Subcutaneous octreotide therapy for malignant pleural effusion after pleurodesis with talc powder: a placebo-controlled, triple-blind, randomized trial

MLA

Reza Ershadi, et al. “Subcutaneous Octreotide Therapy for Malignant Pleural Effusion after Pleurodesis with Talc Powder: A Placebo-Controlled, Triple-Blind, Randomized Trial.” Supportive Care in Cancer, vol. 30, Nov. 2022, pp. 9833–40. EBSCOhost, https://doi.org/10.1007/s00520-022-07440-5.

APA

Reza Ershadi, Matin Vahedi, Hossein Kazemi Zadeh, Farhad Fathi, Hossein Ebrahimpour, Javad Sarbaz Zadeh, & Shahab Rafieian. (2022). Subcutaneous octreotide therapy for malignant pleural effusion after pleurodesis with talc powder: a placebo-controlled, triple-blind, randomized trial. Supportive Care in Cancer, 30, 9833–9840. https://doi.org/10.1007/s00520-022-07440-5

Chicago

Reza Ershadi, Matin Vahedi, Hossein Kazemi Zadeh, Farhad Fathi, Hossein Ebrahimpour, Javad Sarbaz Zadeh, and Shahab Rafieian. 2022. “Subcutaneous Octreotide Therapy for Malignant Pleural Effusion after Pleurodesis with Talc Powder: A Placebo-Controlled, Triple-Blind, Randomized Trial.” Supportive Care in Cancer 30 (November): 9833–40. doi:10.1007/s00520-022-07440-5.